FORTUNE's Best Places to Work Recognizes OhioHealth

FORTUNE's Best Places to Work Recognizes OhioHealth

Central Ohio hospital system claims 2nd highest rank among healthcare systems and the top spot for Ohio-based organizations on FORTUNE's list.

Columbus, OH (PRWEB) February 20, 2009 -- OhioHealth announced today that it has been named one of the country's "100 Best Companies to Work For" by FORTUNE magazine (http://money.cnn.com/magazines/fortune/bestcompanies/2009/) for 2009. This is the third year in a row that OhioHealth has earned the award, reaching #19 in this year's ranking.

OhioHealth was the highest ranked organization in Ohio and the second highest ranked healthcare system (http://www.ohiohealth.com/homepage.cfm) in the nation.

OhioHealth ranking at a glance:

•    OhioHealth is ranked #19 on the list.

•    OhioHealth is ranked #2 for large healthcare systems nationwide.

•    OhioHealth is the highest ranked organization in Ohio. There are five other Ohio organizations on this year's list.

•    OhioHealth is ranked #10 as a large organization.

"We are again honored by FORTUNE's recognition of OhioHealth as one of the best places to work," said Dave Blom, president and CEO of OhioHealth. "It is an affirmation that, together, we have built a strong culture and a healthy work environment that ultimately results in better care for our patients. It is a tribute to our people -- nurses, physicians, staff and volunteers -- to have their work validated by a third party through such a rigorous process. Together, we can take great pride in the work of our associates and all our roles in achieving this award."

FORTUNE magazine's continued recognition of OhioHealth as an employer of choice each year goes beyond the people who are directly involved with patient care. Administrative staff, maintenance, environmental service workers and all of the people who work behind the scenes help contribute to the positive culture that exists at OhioHealth. And it is that positive culture, and OhioHealth's recognition of their service that has helped OhioHealth be successful and to provide thousands of Ohio jobs (http://www.ohiohealth.com/landing.cfm?id=18&fr=true) in our community.

"Every one of our associates contributes to make OhioHealth a great place to work," said Paul Patton, senior vice president of Human Resources and Organizational Development (Interim). "By sharing their talents and skills and modeling the OhioHealth values of compassion, excellence, integrity and stewardship with patients, families and each other, we have created a culture that people want to be a part of. Ultimately, that translates to compassionate and extraordinary patient care and that is the true bottom line for us."

How FORTUNE Picks the 100 Best:

To pick the "100 Best Companies to Work For," FORTUNE works with the Great Place to Work® Institute-a global research and consulting firm with offices in 30 countries-to conduct the most extensive employee survey in corporate America.

More than 81,000 employees from 353 organizations responded to the 57-question survey created by the Institute. Two-thirds of an organization's score is based on the survey, which is sent to a minimum of 400 randomly selected employees. The remaining third is based on an organization's responses to the Culture Audit questionnaire, which asks detailed questions about demographics, pay and benefits, and open-ended questions on philosophy, communication and more.

About OhioHealth:

Named by FORTUNE Magazine as one of the "100 Best Companies to Work For" in 2007, 2008 and 2009, OhioHealth is a nationally recognized, not-for-profit, charitable, healthcare organization serving and supported by the community. Based in Columbus, Ohio, it is a family of 17 hospitals, 23 health and surgery centers, home-health providers, medical equipment and health service suppliers throughout a 40-county area. OhioHealth hospitals in central Ohio are Riverside Methodist Hospital, Grant Medical Center, Doctors Hospital, Grady Memorial Hospital and Dublin Methodist Hospital. For more information, please visit our Web site at http://www.ohiohealth.com/.

###

Contact Information Mark Hopkins

OhioHealth

http://www.ohiohealth.com/

614-544-4248

Endoscopy Systems Market to Reach $4.5 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

Endoscopy Systems Market to Reach $4.5 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

The market for endoscopy systems is projected to reach $4.5 billion by 2015. Growth in this dynamic market is driven by increasing acceptance of endoscopic techniques among physicians, extensive use of endoscopy procedures and technology advancements in areas such as robotics, miniaturization, and imaging.

San Jose, CA (PRWEB) February 19, 2009 -- Endoscopy systems occupy a significant position in the medical device market with applications extending over several areas in medical surgery. The market is driven by an aging population, demand for preventive screening procedures such as colorectal screening, and growing awareness among people towards this medical discipline. Endoscopic procedures are less risky, less painful, and involve lesser patient recovery period, when compared to traditional methods. Owing to escalating opportunities and demand for Minimally Invasive Endoscopy Surgery (MIES) procedures, several medical equipment manufacturers are focusing on developing products that are highly capable of offering minimally invasive surgeries.

US, Japan, and Europe comprise the largest markets, accounting for a major share of the global endoscopy systems market (http://www.strategyr.com/Endoscopy_Systems_Market_Report.asp), as stated in a recent report published by Global Industry Analysts, Inc. Asia-Pacific with increasing penetration of endoscopy procedures represents a potential market for endoscopy systems with CAGR of 5.8% for the next few years. An expanding chronically ill and aging population, improvements in endoscopy technologies and advancements in minimally invasive surgery technologies are driving the endoscopes (http://www.strategyr.com/Endoscopy_Systems_Market_Report.asp) market in the region. Globally, the market for Visualization equipment (http://www.strategyr.com/Endoscopy_Systems_Market_Report.asp) is largely driven by technological advancements such as high-definition camera systems, NBI, MBI technologies, and advancement in video processing, recording, and communication technologies.

Among the application areas, gastrointestinal endoscopy is rapidly trenching new opportunities with growing demand for initial cancer screening tests that facilitates survival prospects of the patient before the risk of metastasis. The segment is also driven by advancements such as capsule endoscopy, which is finding useful application in imaging the gastrointestinal tract including the small intestine. Growth in the market is expected to be further driven by release of novel products and expanding product indications.

The global marketplace is characterized by presence of players such as Boston Scientific Corporation, Conmed Corporation, Ethicon Endo-Surgery, Inc., Fujinon Corp., Given Imaging, Hoya Corporation, Karl Storz GmbH & Co. KG, Medtronic Neurologic Technologies, Olympus Corporation, Richard Wolf Medical Instruments Corporation, Smith & Nephew Plc, and Stryker Corporation.

"Endoscopy Systems: A Global Strategic Business Report", published by Global Industry Analysts, Inc. provides a comprehensive review of major market dynamics, trends, technology advancements, and competition pertaining to the market. The report enumerates recent product introductions/innovations, developments, mergers, acquisitions and other strategic industry activities. Product segments analyzed in the study include Endoscopes and Visualization Equipment. Analysis is presented for the periods 1995-2005 and 2006-2015 for established and emerging markets including the United States, Canada, Japan, France, Germany, United Kingdom, Italy, Spain, Asia-Pacific and Latin America.

For more details about this research report, please visit http://www.strategyr.com/Endoscopy_Systems_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) (http://www.strategyr.com) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs more than 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of more than 60,000 smaller research products including company reports, market trend reports and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.

Telephone 408-528-9966

Fax 408-528-9977

Web Site http://www.StrategyR.com

###

Contact Information Public Relations

Global Industry Analysts, Inc.

http://www.StrategyR.com/

(408) 528-9966

Landmark Trial Provides Vital Information for Cardiac Disease Treatment

Landmark Trial Provides Vital Information for Cardiac Disease Treatment

NorthShore University HealthSystem Ted Feldman, M.D., Lead Investigator

Evanston, IL. -- NorthShore University HealthSystem (http://www.northshore.org/) (NorthShore) has played a leading role in a landmark clinical trial comparing two forms of treatment for patients with severe coronary artery disease (CAD). The results were published on-line in this week's issue of the New England Journal of Medicine.

The SYNTAX trial was a clinical research study that compared percutaneous coronary intervention (PCI) with drug-eluting stents and coronary artery bypass surgery (CABG) in patients with three-vessel and left main coronary disease. The trial results did not show any statistically significant differences between PCI and CABG in rates of death or heart attack, an excess of stroke in the CABG treated patients, and a greater need for repeat PCI procedures in the stent treated patients. These are better outcomes for PCI than have been seen in prior trials in less complex patients.

"At NorthShore, we experienced stunning outcomes in patients whose only option would have previously been bypass surgery," said Ted Feldman, M.D, F.S.C.A.I., Director of Cardiac Catheterization Laboratory, NorthShore University HealthSystem, and a lead investigator of the trial. "The data in this study will provide cardiologists with additional information as they determine treatment therapy for patients with complex CAD."

The trial is the first randomized, controlled clinical trial to compare these two treatments in patients with left main disease and/or three-vessel disease, who are typically treated with CABG and represent a population with far more complex anatomy and advanced disease than those studied in prior drug-eluting stent (DES) clinical trials.

There were 1,800 patients enrolled in the randomized arm of the trial. All patients were assessed by a multidisciplinary team including an interventional cardiologist and a cardiac surgeon. If both the cardiologist and surgeon felt that they could offer equivalent complete revascularization, patients were randomized 1:1 into one of the two treatment strategies. If either the cardiologist or surgeon felt that one or the other revascularization technique was the preferred option, due to technical considerations or co-morbidity, for example, then patients were recruited into one of two parallel, nested registries for PCI or CABG. Thus, patients in the PCI registry had been rejected for cardiac surgery.

About NorthShore University HealthSystem

Headquartered in Evanston, Ill., NorthShore University HealthSystem (NorthShore) is a comprehensive, fully integrated, healthcare delivery system that serves the greater North Shore and northern Illinois communities. The system includes three Hospitals--Evanston Hospital, Glenbrook Hospital and Highland Park Hospital--and a fourth, Skokie-based Rush North Shore Hospital, to be added in January 2009. In addition, the healthsystem has more than 2,000 affiliated physicians, including a 550-physician, multispecialty physician group practice with over 70 office locations-- NorthShore University HealthSystem Medical Group. Further, NorthShore is committed to excellence in its academic mission and supports teaching and research as the principal teaching affiliate of the University of Chicago's Pritzker School of Medicine. The NorthShore University HealthSystem Research Institute, with more than $100 million of grants, focuses on clinical and translational research, including leadership in outcomes research and clinical trials.

NorthShore has annual revenues of $1.5 billion and a staff of more than 8,000. The healthsystem has significant capabilities in a wide spectrum of clinical programs, including cancer, heart, orthopaedics, high-risk maternity and pediatrics. NorthShore is a national leader in the implementation of innovative technologies, including electronic medical records, (EMR ). In 2003, the healthsystem was among the first in the country to successfully launch a systemwide EMR with demonstrable benefits in quality, safety, efficiency and service to patients. NorthShore has been recognized by multiple national organizations for this notable achievement. Visit http://www.northshore.org/

CONTACT: Amy Ferguson

Senior Director, Public Relations

NorthShore University HealthSystem

(847) 570-3146

###

Contact Information Amy Ferguson

Northshore University HealthSystem

http://www.northshore.org/

847-570-3146

Dr. Larry Kaskel, Medical Director of the Heart Attack Prevention Center, to Speak March 4th at CardioCareLive about FirstLine Therapy

Dr. Larry Kaskel, Medical Director of the Heart Attack Prevention Center, to Speak March 4th at CardioCareLive about FirstLine Therapy

CardioCareLive, a medical conference that takes place entirely online, announces participation of Dr. Larry Kaskel, Founder and Medical Director of the Heart Attack Prevention Center. Dr. Kaskel to present "Improved Patient Outcomes and Enhanced Revenue with Therapeutic Lifestyle Changes."

Needham, MA (PRWEB) February 18, 2009 -- CardioCareLive (http://www.cardiocarelive.com), the first of its kind online medical conference for primary care physicians and other healthcare professionals who work with patients with cardiometabolic risk factors, today announced Metagenics as an exhibitor at the March 3-4 event. Metagenics will also sponsor a session by Dr. Larry Kaskel, Founder and Medical Director of the Heart Attack Prevention Center, who will speak on "Improved Patient Outcomes and Enhanced Revenue with Therapeutic Lifestyle Changes." Attendees can watch this live video session and have their questions addressed in near real-time by Dr. Kaskel.

CardioCareLive provides an opportunity for healthcare practitioners to learn and interact with leading practitioners and stay informed about new treatments and therapies for patients with cardiovascular risk factors, such as Metagenics' FirstLine Therapy® program. This turn-key therapeutic lifestyle change program is easy to integrate into a practice and enables primary care physicians to provide lifestyle change therapies in a systematic way that is successful for the patient while also a revenue driver for the practice.

"Physicians recognize the need to guide their patients through lifestyle changes in order to achieve better outcomes," said Mike Katke, VP of Medical Marketing for Metagenics. "But time constraints and practice processes make ongoing care of this type challenging. FirstLine Therapy provides a systematic approach to aid patients in implementing lifestyle changes that can be truly successful."

CardioCareLive recognizes the need for time-constrained physicians to stay current with the latest healthcare innovations. The event delivers all the benefits of a physical medical conference, with live keynote presentations, lectures, peer networking and an exhibit floor, from the convenience of a computer. To view a complete list of speakers, agenda, or to register now for free, visit CardioCarelive.com (http://www.CardioCareLive.com).

About CardioCareLive

CardioCareLive, a medical conference that takes place entirely online, enables healthcare practitioners and others interested in understanding and managing cardiometabolic risk factors to learn, connect and interact through powerful Web-based software and services.

CardioCareLive is produced by PlatformQ (http://www.platformq.com), whose mission is to connect people, companies, organizations and associations worldwide to meet, interact and learn from leading experts and thought leaders through proven interactive tools at online events.

CardioCareLive and PlatformQ are trademarks of PlatformQ, LLC. All other trademarks or service marks are property of their respective owners.

About Metagenics

Metagenics, Inc. (http://www.metagenics.com) is a life sciences company and the premier manufacturer and distributor of science-based medical foods, nutraceuticals and therapeutic lifestyle change programs marketed to healthcare professionals. As a leader in the fields of nutrigenomics and functional medicine, healthcare practitioners around the world rely on Metagenics' products and services to help their patients achieve a lifetime of good health.

Press Contact: Sal Giliberto, 617-938-6006.

###

Contact Information Martha Collins

PlatformQ, LLC.

http://www.CardioCareLive.com

(617) 938-6008